

A burning question from the first international BPAN symposium: is restoration of autophagy a promising therapeutic strategy for BPAN?

Bertrand Mollereau, Susan J Hayflick, Ricardo Escalante, Mario Mauthe, Apostolos Papandreou, Arcangela Iuso, Marion Celle, Sahra Anierte, Abdul Raouf Issa, Jean Paul Lasserre, Gaetan Lesca, Stéphane Thobois, Pauline Burger & Ludivine Walter

To cite this article: Bertrand Mollereau, Susan J Hayflick, Ricardo Escalante, Mario Mauthe, Apostolos Papandreou, Arcangela Iuso, Marion Celle, Sahra Anierte, Abdul Raouf Issa, Jean Paul Lasserre, Gaetan Lesca, Stéphane Thobois, Pauline Burger & Ludivine Walter (2023) A burning question from the first international BPAN symposium: is restoration of autophagy a promising therapeutic strategy for BPAN?, *Autophagy*, 19:12, 3234-3239, DOI: [10.1080/15548627.2023.2247314](https://doi.org/10.1080/15548627.2023.2247314)

To link to this article: <https://doi.org/10.1080/15548627.2023.2247314>



Published online: 31 Aug 2023.



Submit your article to this journal [↗](#)



Article views: 320



View related articles [↗](#)





View Crossmark data [↗](#)

MEETING REPORT



A burning question from the first international BPAN symposium: is restoration of autophagy a promising therapeutic strategy for BPAN?

Bertrand Mollereau ^a, Susan J Hayflick^b, Ricardo Escalante^c, Mario Mauthe^d, Apostolos Papandreou^{e,f}, Arcangela Iuso^{g,h}, Marion Celle^a, Sahra Anierte^a, Abdul Raouf Issa^a, Jean Paul Lasserreⁱ, Gaetan Lesca^{j,k}, Stéphane Thobois^{l,m,n}, Pauline Burger ^o, and Ludivine Walter^a

^aLaboratory of Biology and Modelling of the Cell, ENS of Lyon, University of Lyon, University of Claude Bernard Lyon 1, CNRS UMR 5239, INSERM U1210, UMS 3444 Biosciences Lyon Gerland, Lyon, France; ^bDepartments of Molecular and Medical Genetics, Pediatrics, and Neurology, Oregon Health & Science University, Portland, OR, USA; ^cInstituto de Investigaciones Biomédicas Alberto Sols. CSIC-UAM, Madrid, Spain; ^dDepartment of Biomedical Sciences of Cells & Systems, Molecular Cell Biology Section, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; ^eDevelopmental Neurosciences, Zayed Centre for Research into Rare Disease in Children, University College London Great Ormond Street Institute of Child Health, London, UK; ^fMedical Research Council Laboratory for Molecular Cell Biology, University College London, London, UK; ^gInstitute of Human Genetics, Technische Universität München, Munich, Germany; ^hInstitute of Neurogenetics, Helmholtz Zentrum München, Neuherberg, Germany; ⁱLaboratory of NRGEn, Univ. Bordeaux, CNRS, INCIA, UMR 5287, Bordeaux, France; ^jService de Génétique, Hospices Civils de Lyon, Lyon, France; ^kInstitut Neuromyogène, Laboratoire Physiopathologie et Génétique du Neurone et du Muscle, CNRS UMR 5261-INSERM U1315, Université de Lyon - Université Claude Bernard Lyon 1, Lyon, France; ^lService de Neurologie C, Movement disorders unit, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron, France; ^mInstitut des Sciences Cognitives Marc Jeannerod, UMR 5229, CNRS, Bron, France; ⁿFaculté de Médecine et de Maïeutique Charles Mérieux, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France; ^oInstitut de Génétique et de Biologie Moléculaire et Cellulaire, Université de Strasbourg, INSERM U1258, CNRS UMR7104, Illkirch, France

ABSTRACT

Beta-propeller protein-associated neurodegeneration (BPAN) is a rare neurodegenerative disease associated with severe cognitive and motor deficits. BPAN pathophysiology and phenotypic spectrum are still emerging due to the fact that mutations in the *WDR45* (WD repeat domain 45) gene, a regulator of macroautophagy/autophagy, were only identified a decade ago. In the first international symposium dedicated to BPAN, which was held in Lyon, France, a panel of international speakers, including several researchers from the autophagy community, presented their work on human patients, cellular and animal models, carrying *WDR45* mutations and their homologs. Autophagy researchers found an opportunity to explore the defective function of autophagy mechanisms associated with *WDR45* mutations, which underlie neuronal dysfunction and early death. Importantly, BPAN is one of the few human monogenic neurological diseases targeting a regulator of autophagy, which raises the possibility that it is a relevant model to directly assess the roles of autophagy in neurodegeneration and to develop autophagy restorative therapeutic strategies for more common disorders.

Abbreviations: ATG: autophagy related; BPAN: beta-propeller protein-associated neurodegeneration; ER: endoplasmic reticulum; KO: knockout; NBIA: neurodegeneration with brain iron accumulation; PtdIns3P: phosphatidylinositol-3-phosphate; ULK1: unc-51 like autophagy activating kinase 1; WDR45: WD repeat domain 45; WIPI: WD repeat domain, phosphoinositide interacting.

ARTICLE HISTORY

Received 27 January 2023

Revised 25 July 2023

Accepted 31 July 2023





KEYWORDS

Brain; ferritinophagy; iron; macroautophagy; neurological disease; therapy

Introduction

BPAN, previously known as static encephalopathy of childhood with neurodegeneration in adulthood (SENDA), is an X-linked dominant neurodegenerative disease that has been classified as a neurodegeneration with brain iron accumulation (NBIA) disorder (OMIM 300,894). BPAN is the most recently identified NBIA disorder, and with the increase of BPAN patients diagnosed in the last few years, BPAN has emerged as the most common NBIA disorder with prevalence higher than pantothenate kinase-associated neurodegeneration (PKAN) disease [1,2]. Human and cellular studies have proposed that *WDR45* (OMIM 300,526) variants are causative of a specific NBIA phenotype associated with early

developmental delay, autism, and seizures in childhood, with intellectual disability and neurological deterioration (parkinsonism, dystonia, and dementia) in early adulthood [3–5]. An important genetic hallmark of BPAN is that most mutations are *de novo*, which when associated with the specific clinical features, allows clinicians to establish a BPAN diagnosis. Nevertheless, some ambiguity may remain, in particular with *WDR45* missense mutations, which may require further studies of pathogenicity at the cellular level. Hence, further analyses of derived lymphoblastoid cells or fibroblasts from people with BPAN can be used to establish that *WDR45* variants lead to protein loss and defective autophagy similar to engineered *WDR45* knockout (KO) cells.

CONTACT Bertrand Mollereau  bertrand.mollereau@ens-lyon.fr  Laboratory of Biology and Modelling of the Cell, ENS of Lyon, University of Lyon, University of Claude Bernard Lyon 1, CNRS UMR 5239, INSERM U1210, UMS 3444 Biosciences Lyon Gerland, Lyon, France; Ludivine Walter  ludivine.walter@ens-lyon.fr  Laboratory of Biology and Modelling of the Cell, ENS of Lyon, University of Lyon, University of Claude Bernard Lyon 1, CNRS UMR 5239, INSERM U1210, UMS 3444 Biosciences Lyon Gerland, Lyon, France.

Since the initial discovery of the role of WDR45 in BPAN, research has rapidly grown with several animal and cellular models available to study the function of human WDR45 and its animal homologs. This includes published and ongoing studies in mice [6–9], *Drosophila melanogaster* (BM, MC, SA and LW personal communication), and *Caenorhabditis elegans* [10], *Dictyostelium* [11], as well as several human cell lines carrying *WDR45* mutations (fibroblast, lymphoblast, neuroblastoma) [4,12–14] and induced pluripotent stem cells/iPSCs generated from BPAN human fibroblasts [12]. One reason for this rapid establishment of numerous BPAN

models is that WDR45 is a known regulator of autophagy, which raises important questions about the role of autophagy in the central nervous system development and maintenance [15]. Indeed, several researchers who participated in the BPAN symposium and others have previously published in the autophagy field [16–30]. *WDR45/WIPI4* belongs to the family of WIPI (WD repeat domain, phosphoinositide interacting) proteins also known as beta-propellers that bind phosphoinositides/PROPPINs, including WIPI1, WIPI2, WDR45B/WIPI3 and WDR45, which are all known regulators of autophagy [31,32]. WIPI proteins all contain a conserved F/




Figure 1. The role of WDR45 in autophagy. (A) Schematic representation and 3D structure of WDR45. The 3D structure was generated by Alpha fold structure prediction. The 3D structure of WDR45 and WIPI1, WIPI2 and WDR45B/WIPI3 are similar in which the 7 WD repeats of WDR45 fold into a beta propeller [22]. WD1 to WD7 repeats are represented with the same color codes in the schematic and the 3D structure representation. Mutated residues localized in the PtdIns3P and ATG2 binding domains are shown with red and blue stars, respectively. The mapping of the reported *WDR45* variants is not shown but those variants are distributed throughout the protein domains with no particular hotspots [33]. *WDR45* variants all lead to BPAN, with a broad phenotypic spectrum and varied severity. (B) Schematic representation of the autophagy process and *WDR45* interaction partners. Under fed conditions, *WDR45* interacts with ATG2 in a complex with AMPK and ULK1. In this complex, ULK1 is inactive. Upon starvation and activation of AMPK by STK11/LKB1, the AMPK-ULK1-ATG2-*WDR45* complex dissociates. On the one hand, AMPK activates the ULK1 complex by its phosphorylation and also inhibits MTOR. This results in the activation of the class III phosphatidylinositol 3-kinase complex and PtdIns3P production. On the other hand, the *WDR45*-ATG2 part of the complex is dissociated from the rest of the complex and localizes at the nascent autophagosome, where it presumably promotes maturation. In addition, *WDR45* by interacting with EPG5 favors the fusion of autophagosomes with lysosomes.

LRRG motif, for phosphoinositide binding that allows their association with the cytoplasmic leaflet of organelle membranes (Figure 1A). The detailed comparison of WIPI protein homologies has been recently reported [33]. Based on their amino acid sequence identity, WIPI proteins can be classified into two distinct clades. One clade includes WIPI1 and WIPI2, and the other WDR45B/WIPI3 and WDR45. The strong similarities between the members of the same clade explains their redundant roles in autophagy. In contrast, it was proposed that the function of WDR45 in autophagy could be due to specific interacting partners that are distinct from other WIPI and WDR45 proteins [33–36]. Supporting the fact that the function of WDR45 is distinct from the other WIPI proteins, variants in *WIPI1*, *WIPI2* and *WDR45B/WIPI3* genes do not clearly lead to phenotypes resembling BPAN. However, some levels of redundancy exist between *WIPI* genes, particularly between *WIPI1* and *WIPI2*, and between *WDR45B/WIPI3* and *WDR45* [33,37]. In support of a redundant function of *WIPI* genes in the central nervous system, mutations in *WIPI2* and *WDR45B/WIPI3* genes lead to neurodevelopmental pathologies. These include developmental delay, microcephaly, seizures and progressive neurological deterioration in those harboring *WDR45B/WIPI3* mutations, although reports are still relatively limited and the associated phenotypes are likely to change while larger patient cohorts are being described [38].

What is known so far about the role of WDR45 in autophagy?

Autophagy is an evolutionarily conserved process degrading and recycling cellular contents such as protein aggregates, damaged organelles, and other cytoplasmic materials [39]. Autophagy is characterized by the formation of a phagophore membrane, which expands, resulting in a double-membrane vesicle named an autophagosome. After the fusion of the autophagosome with lysosomes that contain proteases, the sequestered cytoplasmic contents are degraded and recycled [40]. Autophagy is mediated by ATG (autophagy related) proteins in several steps, first the initiation, followed by the phagophore formation and expansion, which sequesters cytoplasmic cargos within the autophagosome (Figure 1B). Essential regulators of autophagy include the nutrient-sensing MTOR (mechanistic target of rapamycin kinase) and AMP-activated protein kinase (AMPK), which phosphorylate ULK1 (unc-51 like autophagy activating kinase 1), the upstream activator of autophagy, leading to its inhibition or activation, respectively. An important upstream complex is the class III phosphatidylinositol 3-kinase complex, which induces the synthesis of phosphatidylinositol-3-phosphate (PtdIns3P) on the phagophore membrane [41]. Another key autophagy protein is MAP1LC3/LC3 (microtubule associated protein 1 light chain 3; Atg8 in yeast), which after conjugation with phosphatidylethanolamine/PE allows the expansion and closure of the phagophore to form an autophagosome. This step is followed by the fusion between the autophagosome and the lysosome, which is mediated by the interaction of the soluble N-ethylmaleimide-sensitive-factor attachment protein receptor/SNARE complex and

EPG5 (ectopic P-granules 5 autophagy tethering factor) proteins, allowing the degradation of cytoplasmic cargos by hydrolytic enzymes within the autolysosome.

Most studies from the last years have reported a role of WDR45 in bulk autophagy, although recent studies have also shown that it could also regulate the selective form of autophagy, ferritinophagy [14,33,37,42,43]. The first striking observation in the analysis of a mice model KO for *Wdr45*, is that the loss of *Wdr45* only led to a partial loss of autophagy, resulting in viable animals carrying neurological syndromes [6–9]. This led to the conclusion that *wdr45*-deficient animal models are useful to study the consequences of partial inhibition of autophagy or inhibition of selective autophagy on the development and maintenance of the nervous system in physiological and pathological conditions.

Mechanistically, WDR45 regulates the autophagy process at different steps. First, it carries conserved motifs that allows its binding to ATG2 and phosphoinositides [36]. By interacting with ATG2 and phosphatidylinositol-3-phosphate on autophagosome membranes, WDR45 favors lipid transfer and elongation of the phagophore controlling the size of the autophagosomes [36]. The importance of the ATG2-WDR45 interaction was challenged in a study showing that the interaction of ATG2 with GABARAP (GABA type A receptor-associated protein) but not with WDR45 plays a major role in autophagy [43]. Second, WDR45 interacts with EPG5, allowing its targeting to late endosomes/lysosomes, hence contributing to the fusion between autophagosome and lysosomes [44]. Thus, in contrast to WIPI1 and WIPI2, which regulate the initiation of autophagy, WDR45 appears to mostly regulate maturation of autophagosomes and their fusion with the lysosomes [35]. And third, WDR45 also interacts with the AMPK-ULK1-ATG2 complex suggesting that WDR45 could also play a role in the initiation of autophagy, although this remains to be functionally tested. Finally, in recent studies, it was observed that *WDR45* KO SH-SY5Y neuroblastoma cell line, BPAN patient primary skin culture, or derived cell line exhibited an accumulation of ferritin and cellular iron [14,42,45]. This accumulation suggests the involvement of WDR45 in ferritinophagy. During ferritinophagy, ferritin proteins are specifically targeted for degradation to the lysosomes through NCOA4 (nuclear receptor coactivator 4), resulting in the release of iron for cellular reuse [46]. However, it remains to be determined whether the binding of WDR45 to the lysosome contributes to the NCOA4-dependent targeting and degradation of ferritin.

Autophagy is particularly important for the homeostasis of non-dividing cells, and it has been proposed that autophagy is an essential mechanism allowing neuronal survival in adult organisms [17]. Hence mice lacking the essential autophagy genes *Atg5* or *Atg7* are not viable. In contrast, conditional KO of these genes in the nervous system provokes spontaneous neurodegeneration due to the lack of basal autophagy [47,48]. These finding, coupled with other studies showing impaired autophagy in neurodevelopmental and neurodegenerative disorders, have led to the hypothesis that restoring autophagy could serve as a putative therapeutic strategy to mitigate neurodegeneration [49,50]. Indeed, there are many (>20) early onset neurodevelopmental disorders and adult-onset

neurodegenerative disorders associated with defects in autophagy [51]. This includes common neurological disorders, such as amyotrophic lateral sclerosis and Parkinson disease but also a broad spectrum of congenital disorders. However, in the great majority of these diseases, autophagy impairment is one of multiple cellular dysregulations or may be the consequence of these dysregulations. For instance, Parkinson disease is considered as a multifactorial and heterogeneous disease. Very few monogenic disorders can be directly attributed to variations in an autophagy gene or a gene encoding a direct regulator of the autophagy pathway. However, there are specific cases where this holds true as BPAN, spinocerebellar ataxia, autosomal recessive 25 with *ATG5* variants, neurodevelopment disorders with *ATG7* variants and amyotrophic lateral sclerosis with SQSTM1/p62 (sequestosome 1) variants [30,52,53]. From these observations, we can hypothesize that the restoration of autophagy might be a particularly relevant strategy to treat those monogenic diseases.

Current status of the autophagy restorative strategy

The fact that autophagy is impacted in BPAN opens the possibility that a pharmacological intervention aiming at restoring functional autophagy could slow down the progression of the disease. Indeed, there is already evidence that autophagy inducers by increasing autophagy activity can restore cellular dysregulations in BPAN cellular models. For example, rapamycin treatment increased autophagy and suppressed tunicamycin-induced apoptosis in HeLa sh*WDR45* cells [7]. In addition, torin treatment activated autophagy and suppressed iron accumulation in *WDR45* mutant human fibroblasts and dopaminergic neurons, respectively [12]. Because of the putative role of *WDR45* in the regulation of ferritinophagy and cellular iron levels [14,42,45], it will be important to determine if autophagy stimulation can restore both ferritinophagy and iron dyshomeostasis in *WDR45* KO models. Although restoring autophagy seems a promising strategy to treat *WDR45* KO cells, further evidence indicates that the loss of *WDR45* leads to multiple cellular defects, which in addition to iron accumulation, may not be solely due to bulk or selective autophagy impairments. This includes ER (endoplasmic reticulum) stress response [7,11,15] and mitochondrial dysfunction [8,12]. Currently, there is no evidence of a role of *WDR45* in reticulophagy or mitophagy, which could suggest a more direct role of *WDR45* at the ER or at the mitochondria to regulate ER stress and mitochondrial function, respectively. Therefore, future strategies targeting autophagy will need to carefully assess whether restoring autophagy is sufficient to suppress all cellular stresses, including iron dyshomeostasis, ER stress and mitochondrial dysfunction induced by *WDR45* mutation. Finally, if autophagy is the primary and causative event in the disease, we expect that autophagy restoration will result in the efficient suppression of neurodegeneration and an improved locomotor function. Such autophagy restoration approaches are awaited in animal models of the disease.

Monogenic rare diseases such as BPAN may also benefit from a gene-based therapy approach to restore *WDR45* expression or autophagy. A logical way to treat BPAN is to

use gene-based therapy by importing a wild type *WDR45* to correct the origin of the disease. Several gene therapy vectors have already reached the market, including one to treat the rare monogenic disorder, Leber congenital amaurosis [54]. The relatively small size of the *WDR45* gene would make it amenable to being incorporated onto a viral vector, but the actual vector type and mode of delivery into the central nervous system and affected cells would have to be carefully considered.

Another possible approach is to induce the expression of an autophagy gene, similarly to what was previously done for spinocerebellar ataxia type 3 (SCA3). In SCA3 mouse models, studies have shown that the injection of a lentiviral vector carrying the *Ulk1* or *Ulk2* gene alleviate the aggregation and SCA3 neuropathology [55]. In BPAN however, the activation of autophagy initiation with ULK1 or ULK2 may not be as effective due to the fact *WDR45* KO cells exhibit a downstream blockade in autophagy at the steps of autophagosomes maturation and degradation by lysosomes [35,56]. A more efficient strategy in BPAN may be to boost lysosomal functions by expressing lysosomal enzymes or providing acidic nanoparticles, which is one current therapeutic strategy in lysosomal storage disorders [57,58]. However, a prior thorough characterization of the autophagy deficit and lysosomal function in *WDR45* KO cells and animal models will be required to envisage such a therapeutic strategy.

Finally, one of the remaining limitations of gene-based (and pharmacological) approaches is to overcome the blood brain barrier to allow the delivery of the molecules to the brain cells. Thus, one of the future challenges, which is currently the purpose of great efforts to treat neurological diseases, is to optimize the delivery of AAV (adeno-associated virus) or other compounds to brain cells [59,60].

Some other outstanding questions related to autophagy and mutations in *WDR45* remain, notably:

- Which tissues and cells are primarily affected by the partial loss of autophagy?
- What is the role of autophagy and *WDR45* in animal neuronal development, and whether the developmental role of *WDR45* contributes to disease in adult?
- What are the primary neuronal networks affected by *WDR45* mutations and whether defects in glial cells contribute the disease?

Description of the symposiums

The first international symposium on BPAN was held on May 13th-14th 2022 at ENS of Lyon, in France. The symposium was organized by the patient organization “Autour du BPAN”, the Hospices Civils of Lyon and researchers at LBMC (ENS-Lyon, CNRS, INSERM, University of Lyon, University of Claude Bernard Lyon 1). Susan J. Hayflick, MD, who discovered that mutations in the *WDR45* gene result in BPAN, was the keynote speaker of the symposium. The first day speakers from France, Germany, the Netherlands, Spain, and the United States reported their findings on

scientific advances on BPAN, followed by a round table. The second day dedicated to the family of patients focused on clinical studies and therapeutic perspectives.

<https://www.autourdubpan.fr/symposium/lang-en/>

The second international symposium on BPAN was organized by the CNRS and Autour du BPAN at the University of Bordeaux, France, on May 12–13th, 2023. It focused on the mechanisms leading to iron accumulation in *WDR45* KO cells, as well as the development of biomarkers and natural history studies for future clinical management. A third symposium will be organized in Paris, for which the topic still remains to be defined.

Acknowledgements

We would like to thank the French family associations “Autour du BPAN” and “BPAN France” for their permanent support to BM, MC, SA and LW.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Funding

BPAN research was supported by “Autour du BPAN”, “BPAN France” JORISS, Fondation Groupama grants to BM, MC, SA and LW. MM, AP, BM and LW were supported by a grant from the Million Dollar Bike Ride program (MDBR-21-123-BPAN and MDR-23-015-NBIABPAN). RI and BM were supported by Marie Skłodowska-Curie Actions (NeuroDiDro - 101067877 - DLV-101067877). RE was supported by grant number PID2021-127355OB-I00 (MCIN/AEI/10.13039/501100011033/FEDER). SJH was supported by the NBIA Disorders Association, Hoffungsbaum e.V., AISNAF, and Isabel's Chance.

ORCID

Bertrand Mollereau  <http://orcid.org/0000-0003-4710-8185>

Pauline Burger  <http://orcid.org/0000-0003-2109-5451>

References

- [1] Wilson JL, Gregory A, Kurian MA, et al. Consensus clinical management guideline for beta-propeller protein-associated neurodegeneration. *Dev Med Child Neurol.* 2021;63(12):1402–1409. doi: [10.1111/dmcn.14980](https://doi.org/10.1111/dmcn.14980)
- [2] Gregory A, Kurian MA, Haack T, et al. Beta-Propeller Protein-Associated Neurodegeneration. In: Margaret PA, Ghayda MM, Roberta AP, et al., editors. *GeneReviews*(R). Seattle (WA): University of Washington, Seattle; 1993.
- [3] Haack TB, Hogarth P, Krueger M, et al. Exome sequencing reveals de novo *WDR45* mutations causing a phenotypically distinct, X-linked dominant form of NBIA. *Am J Hum Genet.* 2012;91(6):1144–1149. doi: [10.1016/j.ajhg.2012.10.019](https://doi.org/10.1016/j.ajhg.2012.10.019)
- [4] Saitsu H, Nishimura T, Muramatsu K, et al. De Novo mutations in the autophagy gene *WDR45* cause static encephalopathy of childhood with neurodegeneration in adulthood. *Nat Genet.* 2013;45(4):445–9, 449e1. doi: [10.1038/ng.2562](https://doi.org/10.1038/ng.2562)
- [5] Adang LA, Pizzino A, Malhotra A, et al. Phenotypic and Imaging spectrum associated with *WDR45*. *Pediatr Neurol.* 2020;109:56–62. doi: [10.1016/j.pediatrneurol.2020.03.005](https://doi.org/10.1016/j.pediatrneurol.2020.03.005)
- [6] Zhao YG, Sun L, Miao G, et al. The autophagy gene *Wdr45/Wipi4* regulates learning and memory function and axonal homeostasis. *Autophagy.* 2015;11(6):881–890. doi: [10.1080/15548627.2015.1047127](https://doi.org/10.1080/15548627.2015.1047127)
- [7] Wan H, Wang Q, Chen X, et al. *WDR45* contributes to neurodegeneration through regulation of ER homeostasis and neuronal death. *Autophagy.* 2019;16(3):531–547.
- [8] Biagosch CA, Vidali S, Faerberboeck M, et al. A comprehensive phenotypic characterization of a whole-body *Wdr45* knock-out mouse. *Mamm Genome.* 2021;32(5):332–349. doi: [10.1007/s00335-021-09875-3](https://doi.org/10.1007/s00335-021-09875-3)
- [9] Noda M, Ito H, Nagata KI. Physiological significance of *WDR45*, a responsible gene for β -propeller protein associated neurodegeneration (BPAN), in brain development. *Sci Rep.* 2021;11(1):22568. doi: [10.1038/s41598-021-02123-3](https://doi.org/10.1038/s41598-021-02123-3)
- [10] Lu Q, Yang P, Huang X, et al. The *WD40* repeat *PtdIns(3)P*-binding protein *EPG-6* regulates progression of omegasomes to autophagosomes. *Dev Cell.* 2011;21(2):343–357. doi: [10.1016/j.devcel.2011.06.024](https://doi.org/10.1016/j.devcel.2011.06.024)
- [11] Tornero-Écija A, Tábara L-C, Bueno-Arribas M, et al. A dictyostelium model for BPAN disease reveals a functional relationship between the *WDR45/WIPI4* homolog *Wdr45l* and *Vmp1* in the regulation of autophagy-associated *PtdIns3P* and ER stress. *Autophagy.* 2021;18(3):1–17. doi: [10.1080/15548627.2021.1953262](https://doi.org/10.1080/15548627.2021.1953262)
- [12] Seibler P, Burbulla LF, Dulovic M, et al. Iron overload is accompanied by mitochondrial and lysosomal dysfunction in *WDR45* mutant cells. *Brain.* 2018;141(10):3052–3064. doi: [10.1093/brain/awy230](https://doi.org/10.1093/brain/awy230)
- [13] Lee JH, Nam SO, Kim EK, et al. Autophagic defects observed in fibroblasts from a patient with β -propeller protein-associated neurodegeneration. *Am J Med Genet A.* 2021;185(12):3866–3871. doi: [10.1002/ajmg.a.62442](https://doi.org/10.1002/ajmg.a.62442)
- [14] Aring L, Choi E-K, Kopera H, et al. A neurodegeneration gene, *WDR45*, links impaired ferritinophagy to iron accumulation. *J Neurochem.* 2022;160(3):356–375. doi: [10.1111/jnc.15548](https://doi.org/10.1111/jnc.15548)
- [15] Mollereau B, Walter L. Is *WDR45* the missing link for ER stress-induced autophagy in beta-propeller associated neurodegeneration? *Autophagy.* 2019;15(12):1–2. doi: [10.1080/15548627.2019.1668229](https://doi.org/10.1080/15548627.2019.1668229)
- [16] Boland B, Yu WH, Corti O, et al. Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing. *Nat Rev Drug Discov.* 2018;17(9):660–688. doi: [10.1038/nrd.2018.109](https://doi.org/10.1038/nrd.2018.109)
- [17] Napoletano F, Baron O, Vandenabeele P, et al. Intersections between regulated Cell death and autophagy. *Trends Cell Biol.* 2019;9(4):323–338. doi: [10.1016/j.tcb.2018.12.007](https://doi.org/10.1016/j.tcb.2018.12.007)
- [18] Fouillet A, Levet C, Virgone A, et al. ER stress inhibits neuronal death by promoting autophagy. *Autophagy.* 2012;8(6):915–926. doi: [10.4161/auto.19716](https://doi.org/10.4161/auto.19716)
- [19] Robin M, Issa AR, Santos CC, et al. *Drosophila p53* integrates the antagonism between autophagy and apoptosis in response to stress. *Autophagy.* 2019;15(5):771–784. doi: [10.1080/15548627.2018.1558001](https://doi.org/10.1080/15548627.2018.1558001)
- [20] Klionsky DJ, Abdel-Aziz AK, Abdelfatah S, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition) 1. *Autophagy.* 2021;17(1):1–382. doi: [10.1080/15548627.2020.1797280](https://doi.org/10.1080/15548627.2020.1797280)
- [21] Dominguez-Martin E, Ongay-Larios L, Kawasaki L, et al. *IreA* controls endoplasmic reticulum stress-induced autophagy and survival through homeostasis recovery. *Mol Cell Biol.* 2018;38(13): doi: [10.1128/MCB.00054-18](https://doi.org/10.1128/MCB.00054-18)
- [22] Vincent O, Antón-Esteban L, Bueno-Arribas M, et al. The *WIPI* gene family and neurodegenerative diseases: Insights from yeast and dictyostelium models. *Front Cell Dev Biol.* 2021;9:737071. doi: [10.3389/fcell.2021.737071](https://doi.org/10.3389/fcell.2021.737071)
- [23] Bueno-Arribas M, Blanca I, Cruz-Cuevas C, et al. A conserved *ATG2* binding site in *WIPI4* and yeast *Hsv2* is disrupted by mutations causing β -propeller protein-associated neurodegeneration. *Hum Mol Genet.* 2021;31(1):111–121. doi: [10.1093/hmg/ddab225](https://doi.org/10.1093/hmg/ddab225)
- [24] Tabara LC, Vincent O, Escalante R. Evidence for an evolutionary relationship between *Vmp1* and bacterial *DedA* proteins. *Int J Dev Biol.* 2019;63(1–2):67–71. doi: [10.1387/ijdb.180312re](https://doi.org/10.1387/ijdb.180312re)
- [25] Tabara LC, Vicente J-J, Biazik J, et al. Vacuole membrane protein 1 marks endoplasmic reticulum subdomains enriched in phospholipid

- synthesizing enzymes and is required for phosphoinositide distribution. *Traffic*. 2018;19(8):624–638. doi: [10.1111/tra.12581](https://doi.org/10.1111/tra.12581)
- [26] Zanuttigh E, Derderian K, Güra MA, et al. Identification of autophagy as a functional target suitable for the pharmacological treatment of mitochondrial Membrane Protein-Associated Neurodegeneration (MPAN) in vitro. *Pharmaceutics*. 2023;15(1):267. doi: [10.3390/pharmaceutics15010267](https://doi.org/10.3390/pharmaceutics15010267)
- [27] Mauthe M, Kampinga HH, Hipp MS, et al. Digest it all: the lysosomal turnover of cytoplasmic aggregates. *Trends Biochem Sci*. 2022;48(3):216–228. doi: [10.1016/j.tibs.2022.09.012](https://doi.org/10.1016/j.tibs.2022.09.012)
- [28] Mauthe M, Dinesh Kumar N, Verlhac P, et al. HSBP1 is a novel interactor of FIP200 and ATG13 that promotes autophagy initiation and picornavirus replication. *Front Cell Infect Microbiol*. 2021;11:745640. doi: [10.3389/fcimb.2021.745640](https://doi.org/10.3389/fcimb.2021.745640)
- [29] Mauthe M, Orhon I, Rocchi C, et al. Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. *Autophagy*. 2018;14(8):1435–1455. doi: [10.1080/15548627.2018.1474314](https://doi.org/10.1080/15548627.2018.1474314)
- [30] Haack TB, Ignatius E, Calvo-Garrido J, et al. Absence of the autophagy adaptor SQSTM1/p62 causes childhood-onset neurodegeneration with ataxia, dystonia, and gaze palsy. *Am J Hum Genet*. 2016;99(3):735–743. doi: [10.1016/j.ajhg.2016.06.026](https://doi.org/10.1016/j.ajhg.2016.06.026)
- [31] Proikas-Cezanne T, Waddell S, Gaugel A, et al. WIPI-1 α (WIPI49), a member of the novel 7-bladed WIPI protein family, is aberrantly expressed in human cancer and is linked to starvation-induced autophagy. *Oncogene*. 2004;23(58):9314–9325. doi: [10.1038/sj.onc.1208331](https://doi.org/10.1038/sj.onc.1208331)
- [32] Bakula D, Mueller AJ, Proikas-Cezanne T. WIPI beta-propellers function as scaffolds for STK11/LKB1-AMPK and AMPK-related kinase signaling in autophagy. *Autophagy*. 2018;14(6):1082–1083. doi: [10.1080/15548627.2017.1382784](https://doi.org/10.1080/15548627.2017.1382784)
- [33] Cong Y, So V, Tijssen MAJ, et al. WDR45, one gene associated with multiple neurodevelopmental disorders. *Autophagy*. 2021;17(12):1–16. doi: [10.1080/15548627.2021.1899669](https://doi.org/10.1080/15548627.2021.1899669)
- [34] Munoz-Braceras S, Tornero-Écija AR, Vincent O, et al. VPS13A is closely associated with mitochondria and is required for efficient lysosomal degradation. *Dis Model Mech*. 2019;12(2): doi: [10.1242/dmm.036681](https://doi.org/10.1242/dmm.036681)
- [35] Bakula D, Müller AJ, Zuleger T, et al. WIPI3 and WIPI4 β -propellers are scaffolds for LKB1-AMPK-TSC signalling circuits in the control of autophagy. *Nat Commun*. 2017;8(1):15637. doi: [10.1038/ncomms15637](https://doi.org/10.1038/ncomms15637)
- [36] Dove SK, Piper RC, McEwen RK, et al. Svp1p defines a family of phosphatidylinositol 3,5-bisphosphate effectors. *EMBO J*. 2004;23(9):1922–1933. doi: [10.1038/sj.emboj.7600203](https://doi.org/10.1038/sj.emboj.7600203)
- [37] Shimizu T, Tamura N, Nishimura T, et al. Comprehensive analysis of autophagic functions of WIPI family proteins and their implications for the pathogenesis of beta-propeller associated neurodegeneration. *Hum Mol Genet*. 2023;32(16):2623–2637. doi: [10.1093/hmg/ddad096](https://doi.org/10.1093/hmg/ddad096)
- [38] Almannai M, Marafi D, El-Hattab AW. WIPI proteins: biological functions and related syndromes. *Front Mol Neurosci*. 2022;15:1011918. doi: [10.3389/fnmol.2022.1011918](https://doi.org/10.3389/fnmol.2022.1011918)
- [39] Nakatogawa H, Suzuki K, Kamada Y, et al. Dynamics and diversity in autophagy mechanisms: lessons from yeast. *Nat Rev Mol Cell Biol*. 2009;10(7):458–467. doi: [10.1038/nrm2708](https://doi.org/10.1038/nrm2708)
- [40] Boya P, Reggiori F, Codogno P. Emerging regulation and functions of autophagy. *Nat Cell Biol*. 2013;15(7):713–720. doi: [10.1038/ncb2788](https://doi.org/10.1038/ncb2788)
- [41] Dikic I, Elazar Z. Mechanism and medical implications of mammalian autophagy. *Nat Rev Mol Cell Biol*. 2018;19(6):349–364. doi: [10.1038/s41580-018-0003-4](https://doi.org/10.1038/s41580-018-0003-4)
- [42] Tsukida K, Muramatsu S-I, Osaka H, et al. WDR45 variants cause ferrous iron loss due to impaired ferritinophagy associated with nuclear receptor coactivator 4 and WD repeat domain phosphoinositide interacting protein 4 reduction. *Brain Commun*. 2022;4(6):fcac 304. doi: [10.1093/braincomms/fcac304](https://doi.org/10.1093/braincomms/fcac304)
- [43] Bozic M, van den Bekerom L, Milne BA, et al. A conserved ATG2-GABARAP family interaction is critical for phagophore formation. *EMBO Rep*. 2020;21(3):e48412. doi: [10.15252/embr.201948412](https://doi.org/10.15252/embr.201948412)
- [44] Ji C, Zhao H, Chen D, et al. β -propeller proteins WDR45 and WDR45B regulate autophagosome maturation into autolysosomes in neural cells. *Curr Biol*. 2021;31(8):1666–1677.e6. doi: [10.1016/j.cub.2021.01.081](https://doi.org/10.1016/j.cub.2021.01.081)
- [45] Diaw SH, Ganos C, Zittel S, et al. Mutant WDR45 leads to altered ferritinophagy and ferroptosis in β -propeller protein-associated neurodegeneration. *Int J Mol Sci*. 2022;23(17):9524. doi: [10.3390/ijms23179524](https://doi.org/10.3390/ijms23179524)
- [46] Quiles Del Rey M, Mancias JD. NCOA4-mediated ferritinophagy: a potential link to neurodegeneration. *Front Neurosci*. 2019;13:238. doi: [10.3389/fnins.2019.00238](https://doi.org/10.3389/fnins.2019.00238)
- [47] Hara T, Nakamura K, Matsui M, et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. *Nature*. 2006;441(7095):885–889. doi: [10.1038/nature04724](https://doi.org/10.1038/nature04724)
- [48] Komatsu M, Waguri S, Chiba T, et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. *Nature*. 2006;441(7095):880–884. doi: [10.1038/nature04723](https://doi.org/10.1038/nature04723)
- [49] Korolchuk VI, Sarkar S, Fanto M. Autophagy in neurodegenerative diseases. *J Mol Biol*. 2020;432(8):2445–2448. doi: [10.1016/j.jmb.2020.03.005](https://doi.org/10.1016/j.jmb.2020.03.005)
- [50] Sanchez-Mirasiera I, Ghimire S, Hernandez-Diaz S, et al. Targeting macroautophagy as a therapeutic opportunity to treat Parkinson's disease. *Front Cell Dev Biol*. 2022;10:921314. doi: [10.3389/fcell.2022.921314](https://doi.org/10.3389/fcell.2022.921314)
- [51] Deneubourg C, Ramm M, Smith LJ, et al. The spectrum of neurodevelopmental, neuromuscular and neurodegenerative disorders due to defective autophagy. *Autophagy*. 2022;18(3):496–517. doi: [10.1080/15548627.2021.1943177](https://doi.org/10.1080/15548627.2021.1943177)
- [52] Kim M, Sandford E, Gatica D, et al. Mutation in ATG5 reduces autophagy and leads to ataxia with developmental delay. *Elife*. 2016;5:5. doi: [10.7554/eLife.12245](https://doi.org/10.7554/eLife.12245)
- [53] Collier JJ, Guissart C, Oláhová M, et al. Developmental consequences of defective ATG7-mediated autophagy in humans. *N Engl J Med*. 2021;384(25):2406–2417. doi: [10.1056/NEJMoa1915722](https://doi.org/10.1056/NEJMoa1915722)
- [54] Yan AL, Du SW, Palczewski K. Genome editing, a superior therapy for inherited retinal diseases. *Vision Res*. 2023;206:108192. doi: [10.1016/j.visres.2023.108192](https://doi.org/10.1016/j.visres.2023.108192)
- [55] Paulino R, Nobrega C. Autophagy in spinocerebellar ataxia type 3: from pathogenesis to therapeutics. *Int J Mol Sci*. 2023;24(8):7405. doi: [10.3390/ijms24087405](https://doi.org/10.3390/ijms24087405)
- [56] Ji C, Zhao YG. The BPAN and intellectual disability disease proteins WDR45 and WDR45B modulate autophagosome-lysosome fusion. *Autophagy*. 2021;17(7):1783–1784. doi: [10.1080/15548627.2021.1924039](https://doi.org/10.1080/15548627.2021.1924039)
- [57] Sevin C, Deiva K. Clinical trials for gene therapy in lysosomal diseases with CNS involvement. *Front Mol Biosci*. 2021;8:624988. doi: [10.3389/fmolb.2021.624988](https://doi.org/10.3389/fmolb.2021.624988)
- [58] Bourdenx M, Daniel J, Genin E, et al. Nanoparticles restore lysosomal acidification defects: implications for Parkinson and other lysosomal-related diseases. *Autophagy*. 2016;12(3):472–483. doi: [10.1080/15548627.2015.1136769](https://doi.org/10.1080/15548627.2015.1136769)
- [59] Le Bras A. Optimizing AAV delivery to the brain. *Lab Anim (NY)*. 2022;51(2):45. doi: [10.1038/s41684-022-00924-1](https://doi.org/10.1038/s41684-022-00924-1)
- [60] Fischell JM, Fishman PS. A multifaceted approach to optimizing AAV delivery to the brain for the treatment of neurodegenerative diseases. *Front Neurosci*. 2021;15:747726. doi: [10.3389/fnins.2021.747726](https://doi.org/10.3389/fnins.2021.747726)